Impact of new drugs and biologics on colorectal cancer treatment and costs

Journal of Oncology Practice

Volumn 7, Issue 3 SUPPL., 2011, Pages

  Karaca Mandic, Pinar ^a,b   McCullough, Jeffrey S ^a,b   Siddiqui, Mustaqeem A ^a,b   Van Houten, Holly ^a,b   Shah, Nilay D ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADULT; ARTICLE; BILLING AND CLAIMS; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER THERAPY; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; DRUG COST; EVIDENCE BASED PRACTICE; FEMALE; FOLLOW UP; HEALTH CARE COST; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; MAJOR CLINICAL STUDY; MALE; MEDICAL SERVICE; MULTIVARIATE ANALYSIS;

EID: 80052698917     PISSN: 15547477     EISSN: 1935469X     Source Type: Journal    
DOI: 10.1200/JOP.2011.000302     Document Type: Article

References (26)

1. Edwards BK, Ward E, Kohler BA, et al: Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 116:544-573, 2009
2. DeVita VT, Schein PS: The use of drugs in combination for the treatment of cancer: Rationale and results. N Engl J Med 288:998, 1973
3. Chu E: Clinical colorectal cancer: Ode to 5-fluorouracil. Clin Colorectal Cancer 6:609, 2007
4. Erlichman C: Fluorouracil and leucovorin for metastatic colorectal cancer. J Chemother 2:38-40, 1990 (suppl 1)
5. Wolpin BM, Mayer RJ: Systemic treatment of colorectal cancer. Gastroenterology 134:1296-1310, 2008
6. Amado RG, Wolf M, Peeters M, et al: Wild-Type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26: 1626-1634, 2008
7. Karapetis CS, Khambata-Ford S, Jonker DJ, et al: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757-1765, 2008
8. Warren JL, Yabroff KR, Meekins A, et al: Evaluation of trends in the cost of initial cancer treatment. J Natl Cancer Inst 100:888-897, 2008 (Pubitemid 351881955)
9. McFarlane J, Riggins J, Smith TJ: SPIKE$: A six-step protocol for delivering bad news about the cost of medical care. J Clin Oncol 26:4200-4204, 2008
10. Meropol NJ, Schulman KA: Cost of cancer care: Issues and implications. J Clin Oncol 25:180-186, 2007 (Pubitemid 350003031)
11. Schrag D: The price tag on progress: Chemotherapy for colorectal cancer. N Engl J Med 351:317-319, 2004
12. Howard DH, Kauh J, Lipscomb J: The value of new chemotherapeutic agents for metastatic colorectal cancer. Arch Intern Med 170:537-542, 2010
13. Ramsey SD, Martins RG, Blough DK, et al: Second-line and third-line chemotherapy for lung cancer: Use and cost. Am J Manag Care 14:297-306, 2008
14. Kutikova L, Bowman L, Chang S, et al: The economic burden of lung cancer and the associated costs of treatment failure in the United States. Lung Cancer 50:143-154, 2005 (Pubitemid 41427890)
15. Cutler D, McClellan M, Newhouse J, et al: Are medical prices declining? Evidence from heart attack treatments. Q J Econ 113:991-1024, 1998
16. Lucarelli C, Nicholson S, Song M: Bundling among rivals: A case of pharmaceutical cocktails. http://www.nber.org/papers/w16321
17. Giantonio BJ, Catalano PJ, Meropol NJ, et al: Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25:1539-1544, 2007 (Pubitemid 46733080)
18. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004 (Pubitemid 38702844)
19. Kabbinavar F, Irl C, Zurlo A, et al: Bevacizumab improves the overall and progression-free survival of patients with metastatic colorectal cancer treated with 5-fluorouracil-based regimens irrespective of baseline risk. Oncology 75:215-223, 2008
20. Medicare Prescription Drug, Improvement, and Modernization Act of 2003. Pub L 108-173. December 8, 2003
21. Ganguli A, Hong SH: Impact of new antihypertensive drugs on the healthcare utilization of hypertensive patients. Am J Pharm Benefits 1:138-144, 2009
22. Joyce GF, Goldman DP, Karaca-Mandic P, et al: Impact of specialty drugs on the use of other medical services. Am J Manag Care 14:821-828, 2008
23. Lichtenberg FR: The effect of using newer drugs on admissions of elderly Americans to hospitals and nursing homes: State-level evidence from 1997 to 2003. Pharmacoeconomics 24:5-25, 2006 (suppl 3)
24. Lichtenberg FR: The impact of new drugs on US longevity and medical expenditure, 1990-2003: Evidence from longitudinal, disease-level data. Am Econ Rev 97:438-443, 2007
25. Miller GE, Moeller JF, Stafford RS: New cardiovascular drugs: Patterns of use and association with non-drug health expenditures. Inquiry 42:397-412, 2005
26. Zhang Y, Soumerai SB: Do newer prescription drugs pay for themselves? A reassessment of the evidence. Health Aff (Millwood) 26:880-886, 2007